New Weight Loss Study Finds Zepbound Outperforms Ozempic & Wegovy
REUTERS/Brendan McDermid/File Photo
Ally Reid
Tuesday, July 9th, 2024 10:46am
A new weight loss study has found that drug brands Zepbound and Mounjaro led to more weight loss compared to Ozempic and Wegovy. The active ingredient in Zepbound and Mounjaro is tirzepatide, while the active ingredient in Ozempic and Wegovy is semaglutide. This new study published by JAMA Internal Medicine found patients taking the highest Zepbound dose lost about 21% of their body weight during a 72-week period. Meanwhile, patients on the highest dose of Wegovy lost around 15% of their body weight during a 68-week period. Do you or anyone you know take any of the new weight loss drugs? What has been your or their experience with them?
Latest Posts
-
Social Media Influencing: A Career Now Recognized by Colleges
Daily Stories
Could this become a degree?
-
Good News Stories for Monday December 9th
Good News
Obesity is on the decline, the first new asthma treatment in decades and seaweed powered vehicles!
-
TikTok Asks Court To Delay U.S. Ban
Daily Stories
The app may not be accessible in the U.S. January 19